Purdue Pharma L.P. (Research & Development - New Jersey)

62 articles with Purdue Pharma L.P. (Research & Development - New Jersey)

• 

  Judge Demands Sacklers Face the Music for the Damage Purdue Caused

  12/17/2021

  U.S. District Judge Colleen McMahon rejected a bankruptcy plan that shielded the Sackler family from potential lawsuits related to the opioid crisis. 

• Purdue Pharma’s Avrio Health Launches SlowMag® Mg Calm+Sleep

  6/17/2021

  Avrio Health L.P., a subsidiary of Purdue Pharma L.P., announced the launch of SlowMag® Mg Calm+Sleep, a dietary supplement with Magnesium Citrate and Melatonin.

• FDA Accepts Filing of Abbreviated New Drug Application and Grants Priority Review for Nalmefene HCI Injection for the Treatment of Known or Suspected Opioid Overdose

  6/10/2021

  Purdue Pharma L.P. (“Purdue”) announced that FDA has accepted and granted priority review to the company’s Abbreviated New Drug Application for the vial dosage form of nalmefene hydrochloride injection.

• Purdue Pharma L.P. to Begin Soliciting Votes for its Broadly Supported Chapter 11 Plan of Reorganization

  6/3/2021

  Purdue Pharma L.P. announced that the United States Bankruptcy Court for the Southern District of New York has approved, among other things, the adequacy of Purdue’s disclosure statement filed in connection with its chapter 11 plan of reorganization.

• Purdue Pharma’s Avrio Health Launches Betadine® Antiseptic Oral Rinse for Professional Use

  2/8/2021

  Avrio Health L.P., a subsidiary of Purdue Pharma L.P., announced the launch of new Betadine® Antiseptic Oral Rinse, an oral antiseptic pre-procedural rinse.

• Prescription Drug Safety Network Doubles Student Reach During the 2019-2020 Academic Year

  8/25/2020

  80 percent of students in Purdue Pharma’s sponsored regions reported they felt prepared to avoid prescription drug misuse after completing the course

• Purdue Pharma L.P. to Fund Harm Reduction Therapeutics, Inc.’s Development of Over-the-Counter Opioid Overdose Reversal Medication

  6/23/2020

  Purdue Pharma L.P. and Harm Reduction Therapeutics, Inc. (HRT) announced today that Purdue will provide up to $6.5 million of additional financial support to HRT to advance its development of a low-cost, over-the-counter (OTC) naloxone nasal spray in the United States. Naloxone is an opioid antagonist rescue medication used to reverse

• Purdue Pharma Announces Agreement in Principle on Landmark Opioid Litigation Settlement

  9/16/2019

  Purdue Pharma L.P. announced that it has reached an agreement in principle on a framework for settling the U.S. opioid litigation facing the Company with 24 state attorneys general, analogous officials from 5 U.S. territories, the Plaintiffs’ Executive Committee in the multidistrict litigation, and co-lead counsel in the MDL.

• Purdue Pharma L.P. and the National Center for Wellness & Recovery at Oklahoma State University Announce Collaboration Around Research to Address the Opioid Addiction Crisis

  8/15/2019

  Purdue Pharma L.P. (“Purdue”) and the National Center for Wellness & Recovery (the “Center”) at Oklahoma State University today announced an innovative collaboration focused on accelerating solutions to the opioid addiction crisis.

• What Purdue Pharma L.P. Knew About a Oxycontin Ring that Pushed More than 1 Million Pills

  7/11/2016

• Purdue Pharma L.P. Announces Patent Agreement With Egalet And Acura Pharmaceuticals, Inc.

  5/23/2016

• National Sheriffs' Association And Purdue Pharma L.P. Lead Law Enforcement Training On Naloxone

  12/7/2015

• Eisai Company And Purdue Pharma L.P. Enter Worldwide Collaboration To Develop And Commercialize Lemborexant

  8/31/2015

• Purdue Pharma L.P. Launches TeamAgainstOpioidAbuse.com

  8/17/2015

• GlaxoSmithKline Joins Purdue Pharma L.P. in Adopting Apple’s ResearchKit for Drug R&D

  7/14/2015

• Depomed Announces Decision In Inter Partes Review Proceeding Against Purdue Pharma L.P. Confirming Patentability Of All Challenged Claims

  7/9/2015

• Purdue Pharma L.P. Release: Data On Long-Term Safety And Effectiveness Of Hysingla ER (hydrocodone bitartrate) Extended-Release Tablets CII Presented At American Pain Society Scientific Meeting

  5/13/2015

• Purdue Pharma L.P. Release: Abuse, Addiction, And Opioid Poisoning Results In Commercially-Insured Individuals Following Introduction Of Reformulated Oxycontin (oxycodone Hcl Extended-Release Tablets) CII

  3/23/2015

• Purdue Pharma L.P. Release: Hysingla™ ER (hydrocodone bitartrate) Extended-Release Tablets CII Now Available

  1/26/2015

• Esteve S.A. (Laboratorios Del Dr. Esteve S.A.) Could Bank $1 Billion From Mundipharma AG, Purdue Pharma L.P. Pain Pact

  1/12/2015